The Tobacco Exclusion That’s Distorting Every Psychosis-Prevention Trial You’re Running
CHR-P patients smoke at 4.8x the rate of healthy controls. New NAPLS2 neuroimaging data shows why—and why your trial's...
ADHD Dosing Has Two Failure Modes, and Trials Are Designed to Miss Both
A Lancet Psychiatry network meta-analysis of ADHD pharmacotherapy exposes therapeutic inertia and uncritical dose escalation as twin hazards—with direct…
When Your CRO’s Books Were Wrong, Your Trial Budget Probably Was Too
ICON's $158M revenue restatement across 2023–2024 exposes how CRO accounting gaps cascade into site payment delays, contract disputes, and...
Platform Trials Are Neurology’s Best Bet — So Why Is the FDA Still Treating Them Like Experiments?
The Lancet calls MAMS platform trials the fix for neurodegenerative drug failure. With 182 Alzheimer's trials active in 2025,...
Vorasidenib Shows 44.1-Month Median PFS in Grade 2 IDH-Mutant Glioma
Vorasidenib demonstrates 44.1-month median progression-free survival in Grade 2 IDH-Mutant Glioma, with 72% seizure reduction and durable disease control.
Elisrasib Shows 78% Response Rate in First-Line KRAS G12C NSCLC
Elisrasib achieves 78% response rate in KRAS G12C NSCLC monotherapy, outperforming first-generation inhibitors in early Phase I/II data.
HARMONi-6: Ivonescimab Plus Chemo Cuts Death Risk 34% vs PD-1 Inhibitor
Ivonescimab plus chemo reduced death risk 34% versus PD-1 inhibitor in advanced squamous NSCLC, with OS benefit sustained at...
Daraxonrasib Cuts Death Risk 60% in Phase 3 Pancreatic Cancer Trial
Daraxonrasib cuts death risk 60% in Phase 3 pancreatic cancer trial, doubling median overall survival versus chemotherapy in previously...
Apalutamide Plus ADT Reduces Prostate Cancer Metastasis Risk in Phase 3 Trial
Apalutamide plus ADT reduced metastasis risk in Phase 3 trial, delaying subsequent therapy by over two years versus ADT...
Zenas BioPharma Files FDA Application for Obexelimab in IgG4-RD
Zenas BioPharma files FDA application for obexelimab in IgG4-RD, a B cell inhibitor showing 56% flare risk reduction in...